EWA
TRVI icon

EverSource Wealth Advisors’s Trevi Therapeutics TRVI Stock Holding History

EverSource Wealth Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.4K Buy
3,452
+3,441
+31,282% +$50K ﹤0.01% 1615
2026
Q1 		$131 Buy
+11
New +$123 ﹤0.01% 4242
2025
Q3 		– Sell
-1
Closed -$5 – 4477
2025
Q2 		$5 Sell
1
-9
-90% -$56 ﹤0.01% 4240
2025
Q1 		$63 Buy
+10
New +$48 ﹤0.01% 3879

Other funds holding TRVI

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return

EverSource Wealth Advisors's TRVI Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Trevi Therapeutics (TRVI) stake by 31,282% in Q2 2026, buying an estimated $50K and bringing the position to 3,452 shares worth $64.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

EverSource Wealth Advisors first reported a position in TRVI in Q1 2025 and has held it in 4 quarters since. 41 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • EverSource Wealth Advisors held 3,452 shares of Trevi Therapeutics worth $64.4K as of Q2 2026.
  • EverSource Wealth Advisors bought 3,441 Trevi Therapeutics shares in Q2 2026, an estimated $50K.
  • Trevi Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1615 holding.
  • EverSource Wealth Advisors first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 41 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.